Evidence map›Paper›PMID 42176900›Full record

ArticleAntiviral research2026

Identification of Nsp15 inhibitors restoring interferon-dependent antiviral activity against SARS-CoV-2.

Stefania Maloccu, Yuka Otsuka, Elizabeth Molchan, Michelle Foti, Annalaura Paulis, Jyoti Vishwakarma, Paolo Malune, Filippo Cottiglia, Angela Corona, Louis Scampavia and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefania MaloccuDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy.
Yuka OtsukaDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Elizabeth MolchanDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Michelle FotiDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy.
Annalaura PaulisDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy.
Jyoti VishwakarmaDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.
Paolo MaluneDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy.
Filippo CottigliaDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy.
Angela CoronaDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy.
Louis ScampaviaDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Timothy P SpicerDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA.
Enzo TramontanoDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy. Electronic address: tramon@unica.it.
Elisa FanunzaDepartment of Life and Environmental Science, University of Cagliari, Cagliari, Italy. Electronic address: elisa.fanunza@unica.it.

Funding

Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Reuben S Harris, Fang Li · 2022 to 2026
$100.9M
NIAID NIH HHS U19 AI171954
6 · The paper itself

Abstract

The endoribonuclease Nsp15 is essential for coronavirus pathogenesis and evasion of host defenses and is therefore a promising drug target. We determined optimal parameters for an endoribonuclease FRET biochemical assay and use it for a high-throughput drug screen. Measurement of Z'-factor confirmed robust assay performance (Z' = 0.7- 0.9). We screened a commercially available library (LOPAC 1280) and identified three molecules able to inhibit the catalytic endonuclease activity of Nsp15 in the low micromolar range. Among them, a promising hit compound, Reactive Blue 2 showed also anti-SARS-CoV-2 activity with EC

Indexed as

Antiviral AgentsBetacoronavirusEndoribonucleasesEnzyme InhibitorsInterferonsSARS-CoV-2Viral Nonstructural ProteinsAnimalsCell LineChlorocebus aethiopsFluorescence Resonance Energy TransferHigh-Throughput Screening AssaysHumansVero CellsVirus ReplicationAntiviral AgentsEndoribonucleasesEnzyme InhibitorsInterferonsViral Nonstructural ProteinsDrug developmentEndoribonucleaseHTS screeningInterferon systemNsp15Reactive blue 2SARS-CoV-2

Identifiers

PMID42176900
PMCPMC13551574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.